Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Novavax UK Phase 3 COVID-19 vaccine trial
2020-004123-16Phase 3Unknown
- Sponsor
- Novavax
- Start
- Sep 2020
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial in coronavirus disease 2019 (COVID-19) comparing SARS-CoV-2 rS with Matrix-M1 adjuvant with Placebo (2 arms). Primary endpoint: First occurrence of PCR-confirmed symptomatic COVID-19. Status: unknown.
02
Drugs
NVX-CoV2373
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-004123-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004123-16.